## **Core Concept**
The patient's presentation of hypoglycemia with increased insulin levels suggests an insulin-related cause. The C-peptide assay helps differentiate between endogenous and exogenous insulin administration. **C-peptide** is a byproduct of proinsulin conversion to insulin and is secreted in equal amounts with insulin.

## **Why the Correct Answer is Right**
In cases of **endogenous hyperinsulinism** (e.g., insulinoma), both insulin and C-peptide levels would be elevated because the source of insulin is within the body and proinsulin is being converted to insulin and C-peptide. However, in **exogenous insulin administration** (e.g., factitious hypoglycemia), insulin levels would be elevated, but C-peptide levels would be low or normal because exogenous insulin does not contain C-peptide. Given that the patient's C-peptide levels are normal, it suggests that the insulin is not being produced endogenously in excess but is instead being administered externally.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option would imply endogenous hyperinsulinism with elevated C-peptide, which does not match the normal C-peptide levels in the scenario.
- **Option B:** This option might suggest another cause of hypoglycemia not directly related to insulin or C-peptide levels.
- **Option C:** This could imply a different diagnosis not directly linked to the insulin/C-peptide story.
- **Option D:** This would be incorrect because it does not align with the provided clinical scenario and lab results indicating exogenous insulin use.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **C-peptide levels help differentiate between endogenous and exogenous causes of hypoglycemia**. In cases of suspected insulinoma or endogenous hyperinsulinism, a low C-peptide level during hypoglycemia points towards exogenous insulin administration, a fact often exploited by factitious disorder patients.

## **Correct Answer:** . Factitious hypoglycemia (or surreptitious insulin use).